Satsuma Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a STSA research report →
Price Chart
About the company
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative therapies for the rapid relief of migraines. Its lead therapeutic candidate, STS101, is an integrated drug-device system comprising a proprietary dry-powder formulation of dihydroergotamine mesylate.
- CEO
- John A. Kollins MBA
- IPO
- 2019
- Employees
- 25
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on STSA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $36.47M
- P/E
- -0.51
- PEG
- 0.05
- P/S
- 0.00
- P/B
- -0.17
- EV/EBITDA
- -0.35
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 125.24%
- ROIC
- -149.15%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-70,947,000
- Net Income
- $-69,163,000-34.9%
- EPS
- $-2.16-22.7%
- OCF Growth
- -19.8%
- FCF Growth
- -15.5%
- 52W High
- $8.08
- 52W Low
- $0.59
- 50D MA
- $0.99
- 200D MA
- $2.18
- Beta
- 0.10
- RSI (14)
- 61
- Avg Volume
- 1.11M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Sterling posted another solid quarter with higher net income, improving credit and funding costs, and continued loan growth, while merger planning with Umpqua remained on track.· January 31, 2014
- Q4 net income was $22.2 million, or $0.35 per share, up from $21.0 million and $0.33 in the prior quarter.
- Tax-equivalent net interest margin was 3.58%, with average deposit costs falling to 31 basis points, the 28th straight quarter of funding cost reductions.
- Asset quality improved further: nonperforming assets to assets fell to 1.21% and the credit allowance declined to 1.99% of loans.
- Gross portfolio loans ended at $7.5 billion, up $304 million in the quarter, with annualized organic loan growth of 10%.
- Management said Umpqua merger integration planning is going well and still expects closing in the second quarter of 2014.
- Mortgage banking weakened versus prior periods, with residential mortgage banking revenue of $9.5 million and closed-loan volume of $524 million, down 23% sequentially.
For Q4 2013, Sterling reported net income of $22.2 million, or $0.35 per share, versus $21.0 million, or $0.33 per share, in Q3 and $20.9 million, or $0.33 per share, in Q4 2012. For full-year 2013, net income was $93.6 million, or $1.48 per share, compared with $385.7 million, or $6.14 per share, in 2012; management noted 2012 included a $292 million tax benefit. On a pretax basis, 2013 net income increased $37.8 million, or 40%, year over year. The tax-equivalent net interest margin was 3.58%, down 1 basis point sequentially and up 9 basis points year over year; average deposit costs were 31 basis points, down 4 basis points from Q3 and down 15 basis points year over year. Nonperforming assets to assets were 1.21% at year-end, down from 1.36% in Q3 and 2.28% at year-end 2012. Net charge-offs were $904,000, versus $1.2 million in Q3 and net recoveries of $566,000 a year ago; the allowance for credit losses was $148 million, or 1.99% of loans, versus 2.08% in Q3 and 2.60% a year ago. Non-interest expense was $84.4 million, down from $85.3 million in Q3 and $89.6 million a year ago; merger-related expenses were $3.6 million. Gross portfolio loans ended at $7.5 billion, up $304 million in the quarter, and portfolio originations were $606 million, up 8% year over year. Organic loan growth was 10% for the quarter and $725 million, or 12%, for the full year. The company said it surpassed $10 billion in assets during the quarter, and the Tier 1 common equity ratio at year-end was 11.8%, down about 50 basis points sequentially. For guidance, management expects the effective tax rate to normalize to approximately 34% in 2014 and still expects the Umpqua merger to close in the second quarter of 2014.
Greg Seibly said the quarter reflected disciplined execution across Sterling’s core priorities: lower funding costs, better asset quality, loan growth, expense control, and active capital management. He repeatedly framed the quarter as evidence that the team stayed focused despite merger uncertainty, and he said integration planning with Umpqua is going well. His tone was confident and appreciative, emphasizing that employees are handling the transition well and that Sterling will keep focusing on operating performance until the merger closes.
Pat Rusnak highlighted the core financial trends: a 3.58% tax-equivalent net interest margin, average deposit costs of 31 basis points, and an allowance for credit losses of $148 million, or 1.99% of loans. He also noted non-interest expense of $84.4 million, including $3.6 million of merger-related costs, and said capital remained solid with an 11.8% Tier 1 common equity ratio, 11.6% leverage ratio, and 16.1% total risk-based capital ratio. On taxes, he said Q4 effective tax rate was 24% and expects it to normalize to about 34% in 2014.
Analysts focused on multifamily and C&I originations, mortgage banking trends, the Durbin threshold impact from crossing $10 billion in assets, and Southern California progress. Management said multifamily originations were up about $100 million year over year and expected modest growth from a roughly $1 billion run rate, while C&I new originations had doubled year over year despite some fourth-quarter paydowns. On mortgage banking, they said the pipeline was tracking the industry and that first-quarter seasonality usually makes the pipeline softer. They also said crossing $10 billion could add about $6 million annually in fees starting in July if the merger were delayed, and they described Southern California as moving from a fledgling operation to a meaningful one with more momentum expected in 2014.
The call showed broad operating momentum: deposits got cheaper, asset quality improved, loan growth stayed strong, and expenses ticked down. Management also sounded confident that merger integration is progressing smoothly and that key growth platforms like multifamily, C&I, SBA, and Southern California are still expanding.
Mortgage banking was a clear weak spot, with revenue down to $9.5 million from $13.5 million sequentially and closed-loan volume down 23%. The company also crossed the $10 billion asset threshold, which brings Durbin-related fee pressure, and management noted merger-related distractions plus ongoing pricing pressure in multifamily and some lumpiness from loan paydowns and mortgage seasonality.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 45.9%
- Shares Outstanding
- 33.15M
- Float Shares
- 15.20M
of shares held by institutions
36 13F filers
Buy/sell ratio 0.07. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Tpg Group Holdings (Sbs) Advisors, Inc. | 1.89M | 0 |
| Marshall Wace North America L.P. | 16.89K | ▼ 1.75K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 8, 23 | RA CAPITAL MANAGEMENT, L.P. | sell | 30,000 |
| Jun 8, 23 | RA CAPITAL MANAGEMENT, L.P. | sell | 20,000 |
| Jun 8, 23 | RA CAPITAL MANAGEMENT, L.P. | sell | 10,000 |
| Jun 8, 23 | RA CAPITAL MANAGEMENT, L.P. | other | 5,914,252 |
| Jun 8, 23 | O'Neil Thomas P. | sell | 80,000 |
| Jun 8, 23 | O'Neil Thomas P. | sell | 72,340 |
| Jun 8, 23 | O'Neil Thomas P. | sell | 76,595 |
| Jun 6, 23 | O'Neil Thomas P. | other | 13,877 |
| Jun 8, 23 | O'Neil Thomas P. | sell | 190,000 |
| Jun 8, 23 | O'Neil Thomas P. | sell | 60,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our STSA coverage
Recent articles, reports, and earnings notes.
No research on STSA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate STSA report →Satsuma Pharmaceuticals Announces Presentation of Two Clinical Program Abstracts at the American Headache Society's 68th Annual Scientific Meeting
prnewswire.com · Jun 4
Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache
prnewswire.com · Nov 5
Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific Meeting
prnewswire.com · Jun 19
Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
prnewswire.com · Apr 30
Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura
prnewswire.com · Nov 26
Satsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without Aura
prnewswire.com · Oct 30
Satsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS Drugs
prnewswire.com · Oct 8
Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 66th Annual Scientific Meeting
prnewswire.com · Jun 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.